Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,866 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 823
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +18.8%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (418)

clinicaltrialsPublishedShowing 701–750 of 1,116 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03690895	Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy(LCPVIH)	completed	—	51	Fondation Ophtalmologique Adolphe de RothschildNETWORK	1	Oct 1, 2018	clinicaltrials
NCT00433381	Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma	completed	Phase 2	123	National Cancer Institute (NCI)